表皮生長因子受體(EGFR)單克隆抗體
Monoclonal Antibody to Epidermal Growth Factor Receptor (EGFR)
ErbB-1; ErbB1; ER1; ERB-B1; MENA; HER1; Erythroblastic Leukemia Viral(v-Erb-B)oncogene Homolog,Avian; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1
- 編號MAA757Hu25
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 來源單抗制備
- 宿主小鼠
- 效價(克隆號)C19
- Ig亞型 IgG2a Kappa
- 純化方式蛋白A + 蛋白G親和純化
- 標(biāo)記物無標(biāo)記物
- 免疫原 RPA757Hu02-表皮生長因子受體(EGFR)重組蛋白
- 緩沖液成份0.01M 磷酸鹽緩沖液(pH7.4,containing 0.05% Proclin-300,50% glycerol)
- 性狀液體
- 濃度1mg/ml
- 且適物種-
- 應(yīng)用WB; IHC; ICC; IP.
如果抗體需用于流式細胞術(shù),請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價格 ¥ 652 ¥ 1520 ¥ 2172 ¥ 5430 ¥ 21720
- 欲了解實際交易價格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
該抗體是針對EGFR的小鼠單克隆抗體。在免疫組織化學(xué)染色和免疫印跡實驗中能識別EGFR。
用法
Western blotting: 0.04-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲,損失率低于5%。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
編號 | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
APA757Hu01 | 表皮生長因子受體(EGFR)活性蛋白 | Cell?culture;?Activity?Assays. |
APA757Hu02 | 表皮生長因子受體(EGFR)活性蛋白 | Cell?culture;?Activity?Assays. |
APA757Hu62 | 表皮生長因子受體(EGFR)活性蛋白 | Cell?culture;?Activity?Assays. |
RPA757Hu01 | 表皮生長因子受體(EGFR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APA757Hu61 | 表皮生長因子受體(EGFR)活性蛋白 | Cell?culture;?Activity?Assays. |
EPA757Hu62 | 表皮生長因子受體(EGFR)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA757Hu02 | 表皮生長因子受體(EGFR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
EPA757Hu61 | 表皮生長因子受體(EGFR)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA757Hu06 | 表皮生長因子受體(EGFR)多克隆抗體 | WB; IHC; ICC; IP. |
PAA757Hu02 | 表皮生長因子受體(EGFR)多克隆抗體 | WB; IHC; ICC; IP. |
PAA757Hu01 | 表皮生長因子受體(EGFR)多克隆抗體 | WB; IHC; ICC; IP. |
FAA757Hu51 | 抗表皮生長因子受體(EGFR)多克隆抗體(別藻藍蛋白標(biāo)記) | FCM |
MAA757Hu27 | 表皮生長因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
MAA757Hu29 | 表皮生長因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
RAA757Hu21 | 表皮生長因子受體(EGFR)重組抗體 | WB; IF; ICC; IHC; IP; FCM. |
MAA757Hu21 | 表皮生長因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
MAA757Hu23 | 表皮生長因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
MAA757Hu24 | 表皮生長因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
MAA757Hu25 | 表皮生長因子受體(EGFR)單克隆抗體 | WB; IHC; ICC; IP. |
MAA757Hu22 | 表皮生長因子受體(EGFR)單克隆抗體 | WB; IHC |
SEA757Hu | 表皮生長因子受體(EGFR)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
HEA757Hu | 表皮生長因子受體(EGFR)檢測試劑盒(酶聯(lián)免疫吸附試驗法,高敏型) | Enzyme-linked immunosorbent assay for Antigen Detection. |
AEA757Hu | 抗表皮生長因子受體抗體(Anti-EGFR)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antibody Detection. |
LMA757Hu | 表皮生長因子受體(EGFR)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
雜志 | 參考文獻 |
Thoracic Cancer | Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer [Wiley: source] |
J Cent Nerv Syst Dis.? | Increased Epidermal Growth Factor Receptor (EGFR) Associated with Hepatocyte Growth Factor (HGF) and Symptom Severity in Children with Autism … [Pubmed:25249767] |
Mol Cancer Ther | GC1118, an anti-EGFR antibody with a distinct binding epitope and superior inhibitory activity against high-affinity EGFR ligands [PubMed: 26586721] |
Cell Death Dis.? | LINC01225 promotes occurrence and metastasis of hepatocellular carcinoma in an epidermal growth factor receptor-dependent pathway [Pubmed:26938303] |
analytica chimica acta | Microfluidic immunosensor based on mesoporous silica platform and CMK-3/poly-acrylamide-co-methacrylate of dihydrolipoic acid modified gold electrode for cancer biomarker detection. [pubmed:28335979] |
Talanta | EGFR detection in extracellular vesicles of breast cancer patients through immunosensor based on silica-chitosan nanoplatform [Doi: 10.1016/j.talanta.2018.10.016] |
Bioorganic Chemistry | Design, synthesis, molecular docking and biological activity evaluation of some novel indole derivatives as potent anticancer active agents and apoptosis inducers [Pubmed: 30665034] |
Journal of?enzyme?inhibition and medicinal chemistry | Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile [Pubmed: 30919701] |
Bioorganic Chemistry | Design and synthesis of new benzoxazole/benzothiazole-phthalimide hybrids as antitumor-apoptotic agents [] |
Bioorganic Chemistry | Synthesis and anticancer activity of bis-benzo [d][1, 3] dioxol-5-yl thiourea derivatives with molecular docking study [Pubmed: 31288134] |
Oxidative Medicine and Cellular Longevity | Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters?… [Pubmed: 31737175] |
Neoplasia | Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine [Pubmed: 33212364] |
Association between Serum Epidermal Growth Factor Receptor and Cyclooxygenase-2 Levels in Patients with Non-small Cell Carcinoma of Lung [] | |
Synthesis, EGFR-TK inhibition and anticancer activity of new quinoxaline derivatives [] | |
IMMUNOLOGIC RESEARCH | Humoral immune response to epidermal growth factor receptor in lung cancer [33495907] |
European Journal of Medicinal Chemistry | Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure¨Cactivity relationship and biological activity as potential antitumor and anticonvulsant agents [33545637] |
Journal of Molecular Structure | Design, synthesis, antiproliferative evaluation, and molecular docking study of new quinoxaline derivatives as apoptotic inducers and EGFR inhibitors [] |
ACS Appl Mater Interfaces | Emitter–Quencher Pair of Single Atomic Co Sites and Monolayer Titanium Carbide MXenes for Luminol Chemiluminescent Reactions [34914377] |
Bioorganic Chemistry | Discovery of new pyrimido [5, 4-c] quinolines as potential antiproliferative agents with multitarget actions: Rapid synthesis, docking, and ADME studies [Pubmed:35219045] |
留言咨詢